劇症肝炎に対するSPE+HFCHDF(<特集>劇症肝炎の治療をめぐって)

概要

論文の詳細を見る
The efficacy of artificial liver support (ALS) has been greatly improved in recent years. We have established SPE plus HFCHDF that can overcome adverse effects such as hypernatremia, metabolic alkalosis and abrupt drop in colloid osmotic pressure (COP), which develop when conventional PE alone is performed. SPE plus HFCHDF is more advantageous for improving the recovery rate from hepatic coma than conventional PE alone. Utilizing it, we have encountered long-term survivors with FH whose liver functions were almost completely lost. However, we need to perform liver transplantations, if the patient's liver functions do not recover after medical treatment including ALS. Even in such cases, the application of SPE plus HFCHDF can gain time while awaiting transplantation as well as time for functional recovery and regeneration of the liver graft following receipt of a graft with marginal function and/or size. Thus, this treatment will greatly contribute to the expansion of the indications for liver transplantation and improvement in the survival from FH.
日本アフェレシス学会の論文
2003-10-31